This clinical study aims to compare the safety and effectiveness of two treatments-oral Tacrolimus capsules and Dexamethasone micro-pulse therapy-in children aged 4-12 years with rapidly progressing vitiligo. The study is a multicenter, randomized, controlled trial involving 90 participants, who will be divided equally into two groups. One group will receive daily Tacrolimus, while the other will take Dexamethasone on weekends. Over 24 weeks, doctors will monitor improvements in skin repigmentation, side effects, and overall health through regular check-ups and blood tests. The goal is to determine which treatment better controls disease progression and improves quality of life for children with vitiligo. Key Points: • For children with rapidly spreading vitiligo. • Compares two common medications. • Follows participants for 6 months. • Focuses on safety and effectiveness.

What is being studied: drugs — Tacrolimus, Dexamethasone.

Who can take part: ages 4 Years to 12 Years, 90 participants planned.

Enrollment status: the registry has not updated this study since its planned completion date, so its current status is unclear. The study started 01 April 2025 and was due to finish 01 April 2026.

Contact: Zhe Jian, Associate Professor.

Source: ClinicalTrials.gov, NCT06900777 (https://clinicaltrials.gov/study/NCT06900777).